Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 11, 2026, 10:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Primary Heart Transplant Clear all

Conditions: Coronary Artery Stenosis, Myocardial Revascularization, Myocardial Ischemia
Interventions: Percutaneous Coronary Intervention, Coronary Artery Bypass Grafting; Procedure
Lead sponsor: Ministry of Science and Higher Education, Poland; Government
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Bryn Mawr, Pennsylvania • San Antonio, Texas

Conditions: DiGeorge Syndrome, Complete Typical DiGeorge Anomaly
Interventions: Cultured Thymus Tissue for Implantation (CTTI); Biological
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: Not listed
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cardiovascular Disease
Interventions: Hemolink (hemoglobin raffimer IV solution); Drug
Lead sponsor: Hemosol; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 19
States / cities: San Francisco, California • Stanford, California • Sarasota, Florida + 14 more

Conditions: Bloodloss, Surgical Procedures, Operative
Interventions: ecallantide, placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 85 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Birmingham, Alabama • Montgomery, Alabama • Aurora, Colorado + 14 more

Conditions: Blood Loss, Surgical
Interventions: Ecallantide, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more

Conditions: Cardiac Allograft Vasculopathy
Interventions: Thymoglobulin; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection
Interventions: Letermovir, Valganciclovir; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: New York, New York

Conditions: Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation, DiGeorge Syndrome, STAT 1 Gain of Function, STAT 3 Gain of Function, Hypomorphic RAG1 Deficiency, CD40 Ligand Deficiency, Mendelian Susceptibility to Mycobacterial Disease, GATA2 Associated Immunodeficiency, CD40 Deficiency, Hypomorphic RAG2 Deficiency, Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome, Omenn Syndrome, Chronic Granulomatous Disease
Interventions: Hematopoietic stem cell transplant (HSCT); Biological
Lead sponsor: Paul Szabolcs; Other
Eligibility: 5 Years to 40 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Primary Heart Transplant, Heart Transplantation, Heart Transplant
Interventions: bortezomib, plasmapheresis; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Beverly Hills, California • San Francisco, California • New Haven, Connecticut + 9 more

Conditions: Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Hyper-IgM, DiGeorge Syndrome, Chediak-Higashi Syndrome, Common Variable Immune Deficiency, Immune Dysregulatory Disorders, Hemophagocytic Lymphohistiocytosis, IPEX, Autoimmune Lymphoproliferative Syndrome, X-linked Lymphoproliferative Syndrome
Interventions: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Up to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Heart Transplantation
Interventions: Thymoglobulin, Mycophenolate Mofetil, Tacrolimus, Sirolimus, Corticosteroids; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Cardiac Transplantation
Interventions: Daclizumab; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Month to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions: Percutaneous Coronary Intervention, CABG; Device · Procedure
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Santa Clara, California

Search by objective public record fields.

Study of Unprotected Left Main Stenting Versus Bypass Surgery (LE MANS Study)

Thymus Transplantation in DiGeorge Syndrome #668

Phase II Study To Evaluate The Safety and Efficacy of Hemoglobin Raffimer in Patients Undergoing First Time CABG Surgery

A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume

Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement

A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation

Immune Disorder HSCT Protocol

The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients

Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients

EXCEL Clinical Trial